ACM
JBIO

ADAR1 Capital Management’s Jade Biosciences JBIO Stock Holding History

ADAR1 Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-71
Closed -$4.15K – 288
2024
Q2 		$4.15K Buy
+71
New +$47.1K ﹤0.01% 246

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ADAR1 Capital Management's JBIO Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Jade Biosciences (JBIO) stake by 4.8% in Q1 2026, selling an estimated $14.5K and leaving 20,000 shares worth $281K. The position accounts for 0.02% of the portfolio, ranked #243.

ADAR1 Capital Management first reported a position in JBIO in Q1 2024 and has held it in 7 quarters since. The position peaked at $3.67M in Q1 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • ADAR1 Capital Management held 20,000 shares of Jade Biosciences worth $281K as of Q1 2026.
  • ADAR1 Capital Management sold 1,000 Jade Biosciences shares in Q1 2026, an estimated $14.5K.
  • Jade Biosciences made up 0.02% of ADAR1 Capital Management's portfolio in Q1 2026, its #243 holding.
  • ADAR1 Capital Management first reported a position in Jade Biosciences in Q1 2024 and has held it in 7 quarters since.
  • ADAR1 Capital Management's Jade Biosciences position peaked at $3.67M in Q1 2025.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.